Clin Colon Rectal Surg 2012; 25(04): 204-209
DOI: 10.1055/s-0032-1329390
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Surgical Management of Clostridium difficile Colitis

Ann K. Seltman
1   Colon and Rectal Surgery Associates Ltd., St. Paul, Minnesota
2   Division of Colon and Rectal Surgery, University of Minnesota, St. Paul, Minnesota
› Author Affiliations
Further Information

Publication History

Publication Date:
21 November 2012 (online)

Abstract

Clostridium difficile infection (CDI) will progress to fulminant disease in 3 to 5% of cases. With the emergence of hypervirulent, multidrug-resistant strains, the incidence and severity of disease are continuing to rise. Prompt identification, early resuscitation, and treatment are critical in preventing morbidity and mortality in this increasingly common condition. Discontinuation of antibiotics and treatment with oral vancomycin and intravenous or oral metronidazole are first-line treatments, but complicated cases may require surgery. Subtotal colectomy with ileostomy remains the standard of care when toxic megacolon, perforation, or an acute surgical abdomen is present, but mortality rates are high. Recognition of risk factors for fulminant CDI and earlier surgical intervention may decrease mortality from this highly lethal disease.

 
  • References

  • 1 Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298 (10) 531-534
  • 2 Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978; 75 (5) 778-782
  • 3 Butler M, Bliss D, Drekonja D , et al. Effectiveness of early diagnosis, prevention, and treatment of Clostridium difficile infection. Rockville, MD: U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality; 2011
  • 4 Dallal RM, Harbrecht BG, Boujoukas AJ , et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235 (3) 363-372
  • 5 Sailhamer EA, Carson K, Chang Y , et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009; 144 (5) 433-439 , discussion 439–440
  • 6 Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011; 254 (3) 423-427 , discussion 427–429
  • 7 Leclair MA, Allard C, Lesur O, Pépin J. Clostridium difficile infection in the intensive care unit. J Intensive Care Med 2010; 25 (1) 23-30
  • 8 Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010; 467 (7316) 711-713
  • 9 Bacci S, Mølbak K, Kjeldsen MK, Olsen KE. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis 2011; 17 (6) 976-982
  • 10 Cohen SH, Gerding DN, Johnson S , et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31 (5) 431-455
  • 11 VerLee KE, Finks JL, Wilkins MJ, Wells EV. Michigan Clostridium difficile hospital discharges: frequency, mortality, and charges, 2002–2008. Public Health Rep 2012; 127 (1) 62-71
  • 12 Gravel D, Miller M, Simor A , et al; Canadian Nosocomial Infection Surveillance Program. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009; 48 (5) 568-576
  • 13 Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 2009; 37 (4) 263-270
  • 14 Lamontagne F, Labbé AC, Haeck O , et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245 (2) 267-272
  • 15 Bauer MP, Notermans DW, van Benthem BH , et al; ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377 (9759) 63-73
  • 16 Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004; 47 (10) 1620-1626
  • 17 Nair S, Yadav D, Corpuz M, Pitchumoni CS. Clostridium difficile colitis: factors influencing treatment failure and relapse—a prospective evaluation. Am J Gastroenterol 1998; 93 (10) 1873-1876
  • 18 Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008; 29 (1) 44-50
  • 19 Khanna S, Pardi DS, Aronson SL , et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012; 107 (1) 89-95
  • 20 Dharmarajan T, Sipalay M, Shyamsundar R, Norkus E, Pitchumoni C. Co-morbidity, not age predicts adverse outcome in Clostridium difficile colitis. World J Gastroenterol 2000; 6 (2) 198-201
  • 21 Seder CW, Villalba Jr MR, Robbins J , et al. Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. Am J Surg 2009; 197 (3) 302-307
  • 22 Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34 (11-12) 1269-1281
  • 23 Stevens V, Dumyati G, Brown J, Wijngaarden E. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf 2011; 20 (10) 1035-1042
  • 24 Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol 2012; 46 (5) 397-400
  • 25 Ananthakrishnan AN, Issa M, Binion DG. Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin North Am 2009; 38 (4) 711-728
  • 26 Ananthakrishnan AN, Guzman-Perez R, Gainer V , et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35 (7) 789-795
  • 27 Navaneethan U, Mukewar S, Venkatesh PG, Lopez R, Shen B. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohn's Colitis 2012; 6 (3) 330-336
  • 28 Byrn JC, Maun DC, Gingold DS, Baril DT, Ozao JJ, Divino CM. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 2008; 143 (2) 150-154 , discussion 155
  • 29 Zahariadis G, Connon JJ, Fong IW. Fulminant Clostridium difficile colitis without diarrhea: lack of emphasis in diagnostic guidelines. Am J Gastroenterol 2002; 97 (11) 2929-2930
  • 30 Nelson RL, Kelsey P, Leeman H , et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2011; (9) CD004610
  • 31 Louie TJ, Miller MA, Mullane KM , et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364 (5) 422-431
  • 32 Cornely OA, Crook DW, Esposito R , et al; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12 (4) 281-289
  • 33 Mattila E, Anttila VJ, Broas M , et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis 2008; 40 (9) 702-708
  • 34 Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012; 46 (2) 145-149
  • 35 Mattila E, Uusitalo-Seppälä R, Wuorela M , et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012; 142 (3) 490-496
  • 36 Gash K, Brown E, Pullyblank A. Emergency subtotal colectomy for fulminant Clostridium difficile colitis—is a surgical solution considered for all patients?. Ann R Coll Surg Engl 2010; 92 (1) 56-60
  • 37 Hall JF, Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am J Surg 2008; 196 (3) 384-388
  • 38 Koss K, Clark MA, Sanders DS, Morton D, Keighley MR, Goh J. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 2006; 8 (2) 149-154
  • 39 Pepin J, Vo TT, Boutros M , et al. Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum 2009; 52 (3) 400-405
  • 40 Ali SO, Welch JP, Dring RJ. Early surgical intervention for fulminant pseudomembranous colitis. Am Surg 2008; 74 (1) 20-26
  • 41 Dudukgian H, Sie E, Gonzalez-Ruiz C, Etzioni DA, Kaiser AM. C. difficile colitis—predictors of fatal outcome. J Gastrointest Surg 2010; 14 (2) 315-322